ReadYourDNA

Lansoprazole (Prevacid)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Lansoprazole

What it is

Lansoprazole is a proton pump inhibitor (PPI): it switches off the pumps in the stomach lining that release acid. It is used for heartburn and acid reflux, for stomach and duodenal ulcers, and as part of the treatment that clears Helicobacter pylori. It is sold as Prevacid, among other names.

How genes come into it

Lansoprazole is broken down mainly by the liver enzyme CYP2C19. Poor and intermediate metabolizers keep it in the blood longer, so stomach acid stays lower, and studies link this to higher Helicobacter cure rates; people with the fast *17 version clear it more quickly. CPIC and DPWG have published guidelines on CYP2C19 and lansoprazole, and the US FDA lists an effect on drug levels. A few other genes have been studied, with weaker evidence.

Published guidelines

Clinical guidelines that name a gene for Lansoprazole. They sort people into groups by the gene copies they carry.

CPIC guideline: CYP2C19. Ultrarapid Metabolizer · Rapid Metabolizer · Normal Metabolizer · Likely Intermediate Metabolizer · Intermediate Metabolizer · Likely Poor Metabolizer · Poor Metabolizer · Indeterminate. Moderate. 2021.

DPWG guideline: CYP2C19. Ultrarapid Metabolizer · Rapid Metabolizer · Normal Metabolizer · Likely Intermediate Metabolizer · Intermediate Metabolizer · Likely Poor Metabolizer · Poor Metabolizer · Indeterminate. 2011.

US FDA: CYP2C19. Likely Poor Metabolizer · Poor Metabolizer. Data that Demonstrate a Potential Impact on Pharmacokinetic Properties Only.

What research found

Every published finding on gene variants and Lansoprazole. Upload your DNA file to see which of these rows apply to you.

Rated evidence (4 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*3: Level 1A · replicated. Efficacy: Gastroesophageal Reflux, Helicobacter Infections. 22.

CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9, CYP2C19*17: Level 1A · replicated. Metabolism/PK: Gastroesophageal Reflux. 9.

IL1B rs16944: Level 3. Efficacy: Helicobacter Infections. 3.

ABCB1 rs1045642: Level 3. Metabolism/PK: Gastroesophageal Reflux, Transplantation. 1.

Metabolism (19 findings)

Studies of how quickly the body processes this medication.

ABCB1 rs1045642: Allele G is associated with increased metabolism of lansoprazole as compared to genotype AA.

CYP2C19 CYP2C19 poor metabolizers: CYP2C19 poor metabolizer is associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 normal metabolizer.

CYP2C19 CYP2C19*1: CYP2C19 *1/*1 is associated with decreased exposure to lansoprazole in people with history of gastric bypass surgery.

CYP2C19 CYP2C19*1, CYP2C19*17: CYP2C19 *17/*17 is associated with increased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.

Response (61 findings)

Studies of how well it worked in people carrying a variant.

CYP2C19 CYP2C19 normal metabolizer genotype: CYP2C19 normal metabolizer is associated with decreased clinical benefit to amoxicillin, clarithromycin and lansoprazole in people with Helicobacter Infections as compared to CYP2C19 poor metabolizer.

CYP2C19 CYP2C19 poor metabolizer and intermediate metabolizer genotypes: CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased clinical benefit to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 normal metabolizer.

CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*17: CYP2C19 *1/*1 + *1/*17 are associated with decreased response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*17 + *2/*2.

CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*3: CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Aciphex (PPIs)

Dexilant (PPIs)

Nexium (PPIs)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com